PHILADELPHIA, Feb. 19,
2025 /PRNewswire/ -- Carisma Therapeutics
Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in
macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and
Chief Scientific Officer, will participate in the H.C. Wainwright
3rd Annual Cell Therapy Virtual Conference on
Tuesday, February 25 at 10:30 am ET.
An audio webcast of the event will be available on the
Company's Investor Events section of the Investor
Relations webpage and will be archived for a limited time following
the event.
About Carisma
Carisma Therapeutics is a biopharmaceutical Company pioneering
macrophage engineering to develop groundbreaking therapies for
fibrosis, cancer, and other diseases. With a strong commitment to
patient-centric innovation, Carisma aims to deliver scalable,
next-generation solutions that transform treatment paradigms.
Carisma is headquartered in Philadelphia, PA. For more
information, please visit www.Carismatx.com.
Investors:
Shveta
Dighe
investors@carismatx.com
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-hc-wainwright-3rd-annual-cell-therapy-virtual-conference-302379463.html
SOURCE Carisma Therapeutics Inc.
